---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-24-000107"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:26:18.892424+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axogen Q2 revenue up 25.6% to $47.9M; net loss narrows; raises FY guidance

## Summary
- Revenue $47.9M (+25.6% YoY); net loss $1.9M ($0.04/share) vs $6.7M loss prior year.
- Adjusted net income $2.0M ($0.05/share); adjusted EBITDA $5.6M vs loss $0.2M.
- FY2024 revenue guidance raised to $182-186M; gross margin guidance adjusted to 74-76%.
- Rolling BLA submission for Avance Nerve Graft initiated; expects completion Q3 2024, potential approval mid-2025.
- Launched Avive+ Soft Tissue Matrix in June; Core accounts up 18.7% to 412.

## SEC filing metadata
- accession: 0000805928-24-000107
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592824000107/0000805928-24-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592824000107/axgn-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-24-000107
- JSON: https://secwatch.observer/filing/0000805928-24-000107.json
- Plain text: https://secwatch.observer/filing/0000805928-24-000107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.